ArticleComputational and structural biotechnology journal2025
TMEtyper: A computational method for tumor microenvironment subtyping with applications in immunotherapy.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in natural killer cell immunotherapy for hematologic malignancies.Cancer biology & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The heterogeneity of the tumor microenvironment (TME) is a critical determinant of outcomes in immune checkpoint blockade (ICB) therapy. However, robust methodological frameworks for systematically characterizing this heterogeneity and identifying causal regulators of treatment response are still lacking. Methods: We developed TMEtyper, a comprehensive computational framework for TME characterization. This was achieved by constructing a pan-cancer TME signature that integrates cellular compositions, pathway activities, and intercellular communication networks. We employed consensus clustering coupled with topological feature extraction to delineate seven distinct TME subtypes. Key hub genes specific to each subtype were identified through an integrative machine learning approach, and their regulatory mechanisms were elucidated using structural causal modeling. Results: TMEtyper integrates 231 TME signatures to characterize the TME via network-based clustering, defining seven subtypes with distinct prognostic implications. Its analytical pipeline combines ensemble machine learning with a convolutional neural network for robust subtype classification and employs structural causal modeling to reconstruct underlying regulatory networks. Validation across 11 independent immunotherapy cohorts confirmed its strong predictive power, with the Lymphocyte-Rich Hot subtype being consistently associated with superior clinical outcomes. TMEtyper is implemented as an open-source R package with an interactive web interface, facilitating TME analysis and biomarker discovery for the research community. Conclusions: TMEtyper establishes an integrative framework that advances TME characterization beyond conventional classifications, delivering both biological insights and clinical utility. Its deployment as an accessible analytical resource opens new avenues for personalized immunotherapy strategies and biomarker development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.